Prot #R475-OA-1611: A Phase 3 Randomized, Double-Blind, Multi-Dose, Placebo and Naproxen-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients with Pain Due to Osteoarthritis of the Knee or Hip

Project: Research project

Project Details

StatusFinished
Effective start/end date10/25/17 → 11/25/23

Funding

  • ICON Clinical Research Limited ((OE) Prot #R475-OA-1611 // (OE) Prot #R475-OA-1611)
  • Regeneron Pharmaceuticals, Inc. ((OE) Prot #R475-OA-1611 // (OE) Prot #R475-OA-1611)